Last reviewed · How we verify
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
The study is expected to include 24 patients with metastatic or surgically unresectable relapsed/refractory soft tissue sarcoma confirmed by histological evidence, who have received at least one line of systemic treatment previously. The efficacy and safety of liposome irinotecan combined with temozolomide and bevacizumab in the treatment of relapsed/refractory soft tissue sarcoma will be evaluated.
Details
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | PHASE2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 24 |
| Start date | Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jan 31 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Soft Tissue Sarcoma (Excluding GIST)
Interventions
- Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma
Countries
China